+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oral Biologics & Biosimilars Market Global Report 2020-30

  • ID: 5014049
  • Report
  • April 2020
  • Region: Global
  • 200 pages
  • The Business Research Company
1 of 5

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • 3sbio
  • Aurobindo Pharma Ltd.
  • Chiasma
  • Eli Lilly and Co.
  • Ganlee
  • Innovent
  • MORE
Oral Biologics & Biosimilars Market Market Global Report 2020-30 from the author provides the strategists, marketers and senior management with the critical information they need to assess the global oral biologics & biosimilars market market.

Reasons to Purchase
  • Gain a truly global perspective with the most comprehensive report available on this market covering 12+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3 working days of order.
Description:

Where is the largest and fastest growing market for the oral biologics & biosimilars market? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Oral Biologics & Biosimilars Market market global report from the author answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider oral biologics & biosimilars market market, and compares it with other markets.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market segmentations break down market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
  • The oral biologics & biosimilars market market section of the report gives context. It compares the oral biologics & biosimilars market market with other segments of the oral biologics & biosimilars market market by size and growth, historic and forecast. It analyses GDP proportion, expenditure per capita, oral biologics & biosimilars market indicators comparison.
Scope

Markets Covered: 1) By Therapy: Lymphocyte Modulators; Interleukin Inhibitors; Tumor Necrosis Factor-Alpha Inhibitors; 2) By Disease: Asthma; Crohn'S Disease; Carcinoma; Arthritis; Diabetes; Multiple Myeloma; Enterocolitis; Multiple Sclerosis; Sarcoma; Psoriasis and Others

Companies Mentioned: Novartis; Rani Therapeutics; Eli Lilly and Co.; AstraZeneca plc; Novo Nordisk A/S

Countries: Brazil, China, France, Germany, India, Indonesia, Japan, South Korea, Russia, UK, USA and Australia

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time series: Five years historic and ten years forecast.

Data: Ratios of market size and growth to related markets, GDP proportions, per capita expenditure.

Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

This report will be delivered within 1-3 business days.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3sbio
  • Aurobindo Pharma Ltd.
  • Chiasma
  • Eli Lilly and Co.
  • Ganlee
  • Innovent
  • MORE
1. Executive Summary

2. Oral Biologics & Biosimilars Market Market Characteristics

3. Oral Biologics & Biosimilars Market Market Size And Growth
3.1. Global Oral Biologics & Biosimilars Market Historic Market, 2015 - 2019, $ Billion
3.1.1. Drivers Of The Market
3.1.2. Restraints On The Market
3.2. Global Oral Biologics & Biosimilars Market Forecast Market, 2019 - 2023F, 2025F, 2030F, $ Billion
3.2.1. Drivers Of The Market
3.2.2. Restraints On the Market

4. Oral Biologics & Biosimilars Market Market Segmentation
4.1. Global Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Lymphocyte Modulators
  • Interleukin Inhibitors
  • Tumor Necrosis Factor-Alpha Inhibitors
4.2. Global Oral Biologics & Biosimilars Market Market, Segmentation By Disease, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
  • Asthma
  • Crohn's Disease
  • Carcinoma
  • Arthritis
  • Diabetes
  • Multiple Myeloma
  • Enterocolitis
  • Multiple Sclerosis
  • Sarcoma
  • Psoriasis and Others
5. Oral Biologics & Biosimilars Market Market Regional And Country Analysis
5.1. Global Oral Biologics & Biosimilars Market Market, Split By Region, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion
5.2. Global Oral Biologics & Biosimilars Market Market, Split By Country, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

6. Asia-Pacific Oral Biologics & Biosimilars Market Market
6.1. Asia-Pacific Oral Biologics & Biosimilars Market Market Overview
6.2. Asia-Pacific Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

7. China Oral Biologics & Biosimilars Market Market
7.1. China Oral Biologics & Biosimilars Market Market Overview
7.2. China Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F,$ Billion

8. India Oral Biologics & Biosimilars Market Market
8.1. India Oral Biologics & Biosimilars Market Market Overview
8.2. India Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

9. Japan Oral Biologics & Biosimilars Market Market
9.1. Japan Oral Biologics & Biosimilars Market Market Overview
9.2. Japan Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

10. Australia Oral Biologics & Biosimilars Market Market
10.1. Australia Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

11. Indonesia Oral Biologics & Biosimilars Market Market
11.1. Indonesia Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

12. South Korea Oral Biologics & Biosimilars Market Market
12.1. South Korea Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

13. Western Europe Oral Biologics & Biosimilars Market Market
13.1. Western Europe Oral Biologics & Biosimilars Market Market Overview
13.2. Western Europe Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

14. UK Oral Biologics & Biosimilars Market Market
14.1. UK Oral Biologics & Biosimilars Market Market Overview
14.2. UK Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

15. Germany Oral Biologics & Biosimilars Market Market
15.1. Germany Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

16. France Oral Biologics & Biosimilars Market Market
16.3. France Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

17. Eastern Europe Oral Biologics & Biosimilars Market Market
17.1. Eastern Europe Oral Biologics & Biosimilars Market Market Overview
17.2. Eastern Europe Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

18. Russia Oral Biologics & Biosimilars Market Market
18.1. Russia Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

19. North America Oral Biologics & Biosimilars Market Market
19.1. North America Oral Biologics & Biosimilars Market Market Overview
19.2. North America Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

20. USA Oral Biologics & Biosimilars Market Market
20.1. USA Oral Biologics & Biosimilars Market Market Overview
20.2. USA Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

21. South America Oral Biologics & Biosimilars Market Market
21.1. South America Oral Biologics & Biosimilars Market Market Overview
21.2. South America Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

22. Brazil Oral Biologics & Biosimilars Market Market
22.1. Brazil Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

23. Middle East Oral Biologics & Biosimilars Market Market
23.1. Middle East Oral Biologics & Biosimilars Market Market Overview
23.2. Middle East Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

24. Africa Oral Biologics & Biosimilars Market Market
24.1. Africa Oral Biologics & Biosimilars Market Market Overview
24.2. Africa Oral Biologics & Biosimilars Market Market, Segmentation By Therapy, Historic and Forecast, 2015-2019, 2023F, 2025F, 2030F, $ Billion

25. Oral Biologics & Biosimilars Market Market Competitive Landscape And Company Profiles
25.1. Oral Biologics & Biosimilars Market Market Competitive Landscape
25.2. Oral Biologics & Biosimilars Market Market Company Profiles
25.2.1. Novartis
25.2.1.1. Overview
25.2.1.2. Products and Services
25.2.1.3. Strategy
25.2.1.4. Financial Performance
25.2.2. Rani Therapeutics
25.2.2.1. Overview
25.2.2.2. Products and Services
25.2.2.3. Strategy
25.2.2.4. Financial Performance
25.2.3. Eli Lilly and Co.
25.2.3.1. Overview
25.2.3.2. Products and Services
25.2.3.3. Strategy
25.2.3.4. Financial Performance
25.2.4. AstraZeneca plc
25.2.4.1. Overview
25.2.4.2. Products and Services
25.2.4.3. Strategy
25.2.4.4. Financial Performance
25.2.5. Novo Nordisk A/S
25.2.5.1. Overview
25.2.5.2. Products and Services
25.2.5.3. Strategy
25.2.5.4. Financial Performance

26. Key Mergers And Acquisitions In The Oral Biologics & Biosimilars Market Market

27. Oral Biologics & Biosimilars Market Market Trends And Strategies

28. Oral Biologics & Biosimilars Market Market Future Outlook and Potential Analysis

29. Appendix
29.1. Abbreviations
29.2. Currencies
29.3. Research Inquiries
29.4. About the Publisher
29.5. Copyright And Disclaimer
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3sbio
  • Aurobindo Pharma Ltd.
  • Chiasma
  • Eli Lilly and Co.
  • Ganlee
  • Innovent
  • MORE
The oral biologics and biosimilar market consist of sales of oral biologics and biosimilar products and related services used to treat chronic diseases such as diabetes, arthritis, cancer. Biologics are drugs made from living cells using highly complex technology while biosimilars are created to function similarly to biologics but are not identical to biologics. Biosimilars offer active properties as any licensed biologic drug. The oral biologics and biosimilar market comprise of biologics and biosimilar drugs taken orally for the targeted treatment of Alzheimer's, multiple sclerosis, HIV/AIDS and other serious conditions.

The global oral biologics & biosimilars market was worth $1.15 billion in 2019. It is expected to grow at a compound annual growth rate (CAGR) of 34.31% and reach $3.74 billion by 2023.

The oral biologics and biosimilar market covered inthis report is segmented by therapy into lymphocyte modulators, interleukin inhibitors, tumor necrosis factor-alpha inhibitors. It is also segmetned by disease into asthma, crohn’s disease, carcinoma, arthritis, diabetes, multiple myeloma, enterocolitis, multiple sclerosis, sarcoma, psoriasis and others.

The rising prevalence of chronic diseases such as arthritis, asthma, cancer is expected to be a major driver of the oral biologics and biosimilar market. Long working hours, limited physical activity, unhealthy eating and drinking habits contribute to the prevalence of chronic diseases and biologics are increasingly used to treat these chronic diseases. Biologics activate the immune system response against cancer cells thus helping the immune system to eliminate the cancer cells from the body. According to a United Nations article, by 2030 the proportion of global deaths due to chronic diseases is expected to increase to 70% of total deaths. The global burden of chronic disease is expected to reach about 60%. Therefore, the rise in the prevalence of chronic diseases is projected to propel the demand for biologics and biosimilars, thus driving the biologics and biosimilar market.

Stringent regulations imposed on approval of biosimilar is anticipated to hinder the growth of oral biologics and biosimilar market in the forecast period. The governments of different regions impose different rules regarding the production and use of biologics and biosimilars. Further, issues such as patent infringement or agreement issues restrict the manufacturers of biologics and biosimilars from commercializing the government-approved biosimilars. The US Food and Drug Administration requires a double regulatory approval for biosimilars, restricting the use of biosimilars as an interchangeable drug to biologics whereas, in Europe, the European Medicines Agency (EMA) approves biosimilars as interchangeable products for biologics. In February 2019, out of the total 17 approved biosimilars only 7 biosimilars including 4 originating biologics could enter the US commercial market. The robust government policies for approval of these drugs impact the manufacturers in oral biologics and biosimilar market.

The latest trend in the oral biologics and biosimilar market is the creation of new insulin biosimilars. The key players operating in the oral biologics and biosimilar market are investing in creating a biosimilar copy of insulin. This is also promoting competition among various biosimilar manufacturers. Following the trend, Mylan, a USA based pharmaceuticals company, in partnership with Biocon launched biosimilar insulin glargine named Semglee, in 2019 in Australia. Biocon is an Indian based biopharmaceutical company. In 2019, Oramed Pharmaceuticals, a Jerusalem based pharmaceutical company developed an oral insulin drug named ORMD-0801 to treat type 2 diabetes. Thus, companies in the oral biologics and biosimilar market are investing in the trend of developing biosimilar of insulin to gain profit.

Major players in the market are Novartis, Rani Therapeutics, Eli Lilly and Co., AstraZeneca plc, Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticals, BiosanaPharma, Entera Bio Ltd. and Allergan plc.
Note: Product cover images may vary from those shown
5 of 5
  • Novartis
  • Rani Therapeutics
  • Eli Lilly and Co.
  • AstraZeneca plc
  • Novo Nordisk A/S
  • Biocon Limited
  • Oramed Pharmaceuticals
  • BiosanaPharma
  • Entera Bio Ltd.
  • Allergan plc
  • Emisphere Technologies
  • Enteris BioPharma
  • Chiasma
  • Allena Pharmaceuticals
  • Gelgen
  • Ganlee
  • 3sbio
  • Innovent
  • Retractable Technologies, Inc.
  • Changchun High Tech
  • Dong Bao
  • CP Guojian
  • GlaxoSmithKline Plc.
  • Concord Biotech
  • Aurobindo Pharma Ltd.
  • H. Lundbeck A/S
  • Sanofi-Aventis
  • Roche
Note: Product cover images may vary from those shown
6 of 5

Loading
LOADING...

Adroll
adroll